ReviewCirculation research2012
Role of phospholipid oxidation products in atherosclerosis.
Review in Circulation research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 204 citations in OpenAlex.
- Lipid metabolic networks, Mediterranean diet and cardiovascular disease in the PREDIMED trial.International journal of epidemiology · 2018Trial
- Metabolic Predictors of Incident Coronary Heart Disease in Women.Circulation · 2018Trial
- Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans.Circulation · 2016Trial
- Polyphenol rich olive oils improve lipoprotein particle atherogenic ratios and subclasses profile: A randomized, crossover, controlled trial.Molecular nutrition & food research · 2016Trial
- Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.Journal of the American College of Cardiology · 2015Trial
- Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial.Journal of thrombosis and thrombolysis · 2014Trial
- Linking Lipidomics to Vulnerable Coronary Plaques: A PROSPECT II Substudy.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- Lipoprotein(a) in Coronary Artery Disease and Aortic Stenosis: Pathophysiology, Clinical Impact, Interventional Implications and Emerging Targeted Therapies.Journal of clinical medicine · 2026Review
- Ferroptosis in cardiovascular diseases: molecular mechanisms and a novel therapeutic target.Molecular biomedicine · 2026Review
- Lipoprotein(a) and the Vascular Redox Interface: Linking Arteriosclerosis, Thrombosis, and Vascular Biology.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- Influence of LDL cholesterol and Lp(a) on monocytes and macrophages in atherosclerosis.Biochemia medica · 2025Review
- Lipid Biochemistry and its Role in Human Diseases.Current medicinal chemistry · 2025Review
- Antibodies Against Phosphorylcholine in Prediction of Cardiovascular Disease Among Women: A Population-Based Prospective Cohort Study.JACC. Advances · 2024Article
- Article
- Article
- Macrophage polarization and metabolism in atherosclerosis.Cell death & disease · 2023Review
- Truncated oxidized phospholipids exacerbate endothelial dysfunction and lung injury caused by bacterial pathogens.Cellular signalling · 2023Article
- Article
- Antibodies against Phosphorylcholine-Implications for Chronic Inflammatory Diseases.Metabolites · 2023Review
- Systemic lupus erythematosus and cardiovascular disease.Journal of internal medicine · 2023Review
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
There is increasing clinical evidence that phospholipid oxidation products (Ox-PL) play a role in atherosclerosis. This review focuses on the mechanisms by which Ox-PL interact with endothelial cells, monocyte/macrophages, platelets, smooth muscle cells, and HDL to promote atherogenesis. In the past few years major progress has been made in identifying these mechanisms. It has been recognized that Ox-PL promote phenotypic changes in these cell types that have long-term consequences for the vessel wall. Individual Ox-PL responsible for specific cellular effects have been identified. A model of the configuration of bioactive truncated Ox-PL within membranes has been developed that demonstrates that the oxidized fatty acid moiety protrudes into the aqueous phase, rendering it accessible for receptor recognition. Receptors and signaling pathways for individual Ox-PL species are now determined and receptor independent signaling pathways identified. The effects of Ox-PL are mediated both by gene regulation and transcription independent processes. It has now become apparent that Ox-PL affects multiple genes and pathways, some of which are proatherogenic and some are protective. However, at concentrations that are likely present in the vessel wall in atherosclerotic lesions, the effects promote atherogenesis. There have also been new insights on enzymes that metabolize Ox-PL and the significance of these enzymes for atherosclerosis. With the knowledge we now have of the regulation and effects of Ox-PL in different vascular cell types, it should be possible to design experiments to test the role of specific Ox-PL on the development of atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.